Ridinilazole: a novel antimicrobial for Clostridium difficile infection

Por Cho, Jonathan C., Crotty, Matthew P., Pardo, Joe
Publicado no Ann Gastroenterol (2019)

New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides

Por Crotty, Matthew P., Krekel, Tamara, Burnham, Carey-Ann D., Ritchie, David J.
Publicado no J Clin Microbiol (2016)

1331. Learning Experiences Within Infectious Diseases Pharmacy Residency Programs Demonstrate High Degrees of Consistency

Por Cho, Jonathan, Crotty, Matthew, Kufel, Wesley, Chahine, Elias, Sofjan, Amelia, Gallagher, Jason, Estrada, Sandy
Publicado no Open Forum Infect Dis (2018)

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria

Por Gonzalez, Mark D., McMullen, Allison R., Wallace, Meghan A., Crotty, Matthew P., Ritchie, David J., Burnham, Carey-Ann D.
Publicado no Ann Lab Med (2017)

Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship

Por Crotty, Matthew P., Meyers, Shelby, Hampton, Nicholas, Bledsoe, Stephanie, Ritchie, David J., Buller, Richard S., Storch, Gregory A., Kollef, Marin H., Micek, Scott T.
Publicado no Crit Care (2015)

Epidemiology, Co-Infections, and Outcomes of Viral Pneumonia in Adults: An Observational Cohort Study

Por Crotty, Matthew P., Meyers, Shelby, Hampton, Nicholas, Bledsoe, Stephanie, Ritchie, David J., Buller, Richard S., Storch, Gregory A., Micek, Scott T., Kollef, Marin H.
Publicado no Medicine (Baltimore) (2015)